Antibody biodistribution coefficients: Inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978 · see citing works

Antibody Pharmacokinetics and Pharmacodynamics

Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909 · see citing works

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725 · see citing works

Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

Shah, D. K., & Betts, A. M. (2011) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9232-2 · Cited by 424 · see citing works

Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice

Garg, A., & Balthasar, J. P. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9065-1 · Cited by 329 · see citing works

Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.

Baxter, L. T., Zhu, H. J., Mackensen, D. G., & Jain, R. K. (1994) · PubMed · Cited by 280 · see citing works

Mediated efflux of IgG molecules from brain to blood across the blood–brain barrier

Zhang, Y., & Pardridge, W. M. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00242-9 · Cited by 272 · see citing works

Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

Boswell, C. A., Mundo, E. E., Zhang, C., Bumbaca, D., Valle, N., Kozak, K. R., Fourie, A., Chuh, J., Koppada, N., Saad, O. M., et al. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200212a · Cited by 209 · see citing works

(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.

Perk, L. R., Visser, G. W. M., Vosjan, M. J. W. D., van Walsum, M., Tijink, B. M., Leemans, C. R., & van Dongen, G. A. M. S. (2005) · PubMed · Cited by 205 · see citing works

A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn)

Ferl, G. Z., Wu, A. M., & DiStefano, J. J. (2005) · Annals of Biomedical Engineering · doi:10.1007/s10439-005-7410-3 · Cited by 144 · see citing works

Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice

Xie, H., Audette, C. A., Hoffee, M., Lambert, J. M., & Blättler, W. A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060533 · Cited by 142 · see citing works

The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity

Alley, S. C., Zhang, X., Okeley, N. M., Anderson, M. E., Law, C., Senter, P. D., & Benjamin, D. R. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155549 · Cited by 136 · see citing works

Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting

Danilov, S. M., Gavrilyuk, V., Franke, F. E., Pauls, K., Harshaw, D. W., McDonald, T. D., Miletich, D. J., & Muzykantov, V. R. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.280.6.l1335 · Cited by 135 · see citing works

Investigation of the Influence of FcRn on the Distribution of IgG to the Brain

Garg, A., & Balthasar, J. P. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9129-9 · Cited by 108 · see citing works

Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration

Pepinsky, R. B., Shao, Z., Ji, B., Wang, Q., Meng, G., Walus, L. R., Lee, X., Hu, Y., Graff, C. P., Garber, E. A., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183483 · Cited by 87 · see citing works

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers

Herbertson, R. A., Tebbutt, N. C., Lee, F.-T., MACFARLANE, D. J., Chappell, B., Micallef, N., Lee, S.-T., Saunder, T., Hopkins, W., Smyth, F. E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0536 · Cited by 74 · see citing works

Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque

Matthews, D., Appelbaum, F. R., Eary, J. F., Hui, T., Fisher, D., Martin, P., Durack, L. D., Nelp, W., Press, O. W., & Badger, C. C. (1991) · Blood · doi:10.1182/blood.v78.7.1864.1864 · Cited by 70 · see citing works

Biodistribution of [125I]-labeled therapeutic proteins: Application in protein drug development beyond oncology**All authors are current or former employees of Wyeth, Inc.

Vugmeyster, Y., DeFranco, D., Szklut, P., Wang, Q. L., & Xu, X. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21855 · Cited by 52 · see citing works

Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients.

Buist, M. R., Kenemans, P., den Hollander, W., Vermorken, J. B., Molthoff, C. F. M., Burger, C. W., Helmerhorst, T. J. M., Baak, J. P. A., & Roos, J. C. (1993) · PubMed · Cited by 52 · see citing works

Pharmacokinetic Characteristics and Biodistribution of Radioiodinated Chimeric TNT-1, -2, and -3 Monoclonal Antibodies After Chemical Modification with Biotin

Khawli, L. A., Mizokami, M. M., Sharifi, J., Hu, P., & Epstein, A. L. (2002) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497802760363150 · Cited by 44 · see citing works

Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507

Fleuren, E. D. G., Versleijen‐Jonkers, Y. M. H., van de Luijtgaarden, A. C. M., Molkenboer‐Kuenen, J. D. M., Heskamp, S., Roeffen, M. H. S., van Laarhoven, H. W. M., Houghton, P. J., Oyen, W. J. G., Boerman, O. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1488 · Cited by 43 · see citing works

Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody

van Rij, C. M., Sharkey, R. M., Goldenberg, D. M., Frielink, C., Molkenboer‐Kuenen, J. D. M., Franssen, G. M., van Weerden, W. M., Oyen, W. J. G., & Boerman, O. C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.086520 · Cited by 42 · see citing works

Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms

Vugmeyster, Y., Szklut, P., Tchistiakova, L., Abraham, W. M., Kasaian, M. T., & Xu, X. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2007.12.004 · Cited by 40 · see citing works

Physiologically Based Pharmacokinetics of Cyclosporine A: Reevaluation of Dose–Nonlinear Kinetics in Rats

Tanaka, C., Kawai, R., & Rowland, M. (1999) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1023/a:1020978509566 · Cited by 35 · see citing works

Endotoxin reduces specific pulmonary uptake of radiolabeled monoclonal antibody to angiotensin-converting enzyme.

Muzykantov, V. R., Puchnina, E. A., Atochina‐Vasserman, E. N., Hiemish, H., Slinkin, M. A., Meertsuk, F. E., & Danilov, S. M. (1991) · PubMed · Cited by 30 · see citing works

Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts

Abuqayyas, L., & Balthasar, J. P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9357-2 · Cited by 29 · see citing works

Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/-mice

Vugmeyster, Y., DeFranco, D., Pittman, D. D., & Xu, X. (2010) · mAbs · doi:10.4161/mabs.2.5.13089 · Cited by 25 · see citing works

Pharmacokinetics and Tumor Targeting of 131I-Labeled F(ab9)2 Fragments of the Chimeric Monoclonal Antibody G250: Preclinical and Clinical Pilot Studies

Brouwers, A. H., Mulders, P., Oosterwijk, E., Buijs, W. C. A. M., Corstens, F. H. M., Boerman, O. C., & Oyen, W. J. G. (2004) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2004.19.466 · Cited by 23 · see citing works

In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131–Labeled Monoclonal Antibody 14C5 in a Non–Small Cell Lung Cancer and Colon Carcinoma Model

Burvenich, I. J. G., Schoonooghe, S., Cornelissen, B. T., Blanckaert, P., Coene, E. D., Cuvelier, C. A., Mertens, N., & Slegers, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2503 · Cited by 22 · see citing works

Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131i]iodo-4-phosphonomethylbenzoate ([131i]SIPMB), a negatively charged substituent bearing acylation agent

Shankar, S., Vaidyanathan, G., Affleck, D. J., Peixoto, K. V., Bigner, D. D., & Zalutsky, M. R. (2004) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.04.007 · Cited by 22 · see citing works

Pharmacokinetics and Tumor Targeting of 131I-Labeled F(ab')2 Fragments of the Chimeric Monoclonal Antibody G250: Preclinical and Clinical Pilot Studies

Brouwers, A. H., Mulders, P., Oosterwijk, E., Buijs, W. C. A. M., Corstens, F. H. M., Boerman, O. C., & Oyen, W. J. G. (2004) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/1084978041979607 · Cited by 21 · see citing works

Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab')2 fragments.

Buchegger, F., Chalandon, Y., Pèlegrin, A., Hardman, N., & Mach, J. P. (1991) · PubMed · Cited by 21 · see citing works

Radiolabeling and biodistribution of monoclonal antibody (MAb) anti-CD20 with iodine-131

Akanji, A. G., Muramoto, E., Filho, J. D. S., Couto, R. M., & de Araújo, E. B. (2005) · Brazilian Archives of Biology and Technology · doi:10.1590/s1516-89132005000700010 · Cited by 11 · see citing works

Pharmacokinetics of reshaped MAb 425 in three animal species

Haunschild, J., Steiner, K., Faro, H. P., & Senekowitsch, R. (1995) · Cell Biophysics · doi:10.1007/bf02791578 · Cited by 9 · see citing works

Expression of Human Tumor Mucin-Associated Carbohydrate Epitopes, Including Sialylated Tn, and Localization of Murine Monoclonal Antibodies CC49 and B72.3 in a Syngeneic Rat Colon Carcinoma Model

O’Boyle, K., Goya, V., Zuckier, L. S., Chun, S. H., & Bhargava, K. K. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199411000-00001 · Cited by 5 · see citing works

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 760 · see citing works

The Neonatal Fc Receptor (FcRn): A Misnomer?

Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 432 · see citing works

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

Liming, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 394 · see citing works

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works

Designing antibodies as therapeutics

Carter, P. J., & Rajpal, A. (2022) · Cell · doi:10.1016/j.cell.2022.05.029 · Cited by 275 · see citing works

Engineered human blood–brain barrier microfluidic model for vascular permeability analyses

Hajal, C., Offeddu, G. S., Shin, Y., Zhang, S., Morozova, O. A., Hickman, D., Knutson, C. G., & Kamm, R. D. (2022) · Nature Protocols · doi:10.1038/s41596-021-00635-w · Cited by 263 · see citing works

Challenges and opportunities for non-antibody scaffold drugs

Vazquez-Lombardi, R., Phan, T. G., Zimmermann, C., Lowe, D., Jermutus, L., & Christ, D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.004 · Cited by 226 · see citing works

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-023-00966-w · Cited by 218 · see citing works

In vitro-engineered non-antibody protein therapeutics

Simeon, R. L., & Chen, Z. (2017) · Protein & Cell · doi:10.1007/s13238-017-0386-6 · Cited by 176 · see citing works

Influence of molecular size on tissue distribution of antibody fragments

Li, Z., Krippendorff, B., Sharma, S., Walz, A., Lavé, T., & Shah, D. K. (2015) · mAbs · doi:10.1080/19420862.2015.1111497 · Cited by 173 · see citing works

Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies

Kamath, A. V. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.09.004 · Cited by 158 · see citing works

Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy

Han, L., Liu, C., Qi, H., Zhou, J., Wen, J., Wu, D., Xu, D., Qin, M., Ren, J., Wang, Q., et al. (2019) · Advanced Materials · doi:10.1002/adma.201805697 · Cited by 145 · see citing works

Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: A randomized trial

Boever, E. H. D., Ashman, C., Cahn, A. P., Locantore, N., Overend, P., Pouliquen, I. J., Serone, A., Wright, T. J., Jenkins, M., Panesar, I. S., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.01.002 · Cited by 143 · see citing works

Peptide-based PET quantifies target engagement of PD-L1 therapeutics

Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., Allaj, V., Sysa‐Shah, P., Wharram, B. L., Lesniak, W. G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122216 · Cited by 138 · see citing works

Importance of Drug Pharmacokinetics at the Site of Action

Rizk, M. L., Zou, L., Savić, R. M., & Dooley, K. E. (2017) · Clinical and Translational Science · doi:10.1111/cts.12448 · Cited by 132 · see citing works

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development

Davis, J. D., Padros, M. B., Conrado, D. J., Ganguly, S., Guan, X., Hassan, H. E., Hazra, A., Irvin, S. C., Jayachandran, P., Kosloski, M. P., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3150 · Cited by 119 · see citing works

Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes

Dijk, W., Beigneux, A. P., Larsson, M., Bensadoun, A., Young, S. G., & Kersten, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m067363 · Cited by 119 · see citing works

Antibody Conjugates-Recent Advances and Future Innovations

Leung, D., Wurst, J., Liu, T., Martinez, R., Datta‐Mannan, A., & Feng, Y. (2020) · Antibodies · doi:10.3390/antib9010002 · Cited by 119 · see citing works

Soluble ligands as drug targets

Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 110 · see citing works

Dupilumab: Mechanism of action, clinical, and translational science

McCann, M. R., Kosloski, M. P., Xu, C. R., Davis, J. D., & Kamal, M. A. (2024) · Clinical and Translational Science · doi:10.1111/cts.13899 · Cited by 105 · see citing works

Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice

Dai, C.-L., Hu, W., Tung, Y. C., Liu, F., Gong, C.-X., & Iqbal, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0341-7 · Cited by 99 · see citing works

Absorption, Distribution, Metabolism, and Excretion Considerations for the Development of Antibody-Drug Conjugates

Han, T. H., & Zhao, B. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058586 · Cited by 100 · see citing works

A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design

Vasalou, C., Helmlinger, G., & Gomes, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118977 · Cited by 98 · see citing works

Preclinical proof of principle for orally delivered Th17 antagonist miniproteins

Berger, S., Seeger, F., Yu, T.-Y., Aydin, M., Hui-lin, Y., Rosenblum, D., Guenin‐Macé, L., Glassman, C. R., Arguinchona, L., Sniezek, C. M., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.052 · Cited by 93 · see citing works

Antibody pharmacokinetics in rat brain determined using microdialysis

Chang, H.-Y., Morrow, K., Bonacquisti, E. E., Zhang, W., & Shah, D. K. (2018) · mAbs · doi:10.1080/19420862.2018.1473910 · Cited by 84 · see citing works

Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development

Glassman, P. M., & Balthasar, J. P. (2018) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2018.11.002 · Cited by 86 · see citing works

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study

Hershberger, E., Sloan, S. E., Narayan, K. M., Hay, C. A., Smith, P. F., Engler, F. A., Jeeninga, R. E., Smits, S. L., Trevejo, J., Shriver, Z., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.051 · Cited by 83 · see citing works

Quantification of IgG monoclonal antibody clearance in tissues

Eigenmann, M. J., Fronton, L., Grimm, H. P., Otteneder, M. B., & Krippendorff, B. (2017) · mAbs · doi:10.1080/19420862.2017.1337619 · Cited by 80 · see citing works

The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa

Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 83 · see citing works

Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors

van Oordt, C. W. M. D. H., McGeoch, A. T., Bergström, M., McSherry, I. N., Smith, D. A., Cleveland, M., Al‐Azzam, W., Chen, L., Verheul, H. M. W., Hoekstra, O. S., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.214726 · Cited by 78 · see citing works

Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment

Tang, L., Feng, Y., Gao, S., Mu, Q., & Liu, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.786700 · Cited by 73 · see citing works

Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development

Singh, A. P., Shin, Y. G., & Shah, D. K. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1626-1 · Cited by 70 · see citing works

IgA potentiates NETosis in response to viral infection

Stacey, H. D., Golubeva, D., Posca, A., Ang, J. C., Novakowski, K. E., Zahoor, M. A., Kaushic, C., Cairns, E., Bowdish, D. M. E., Mullarkey, C. E., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101497118 · Cited by 68 · see citing works

Influence of Molecular size on the clearance of antibody fragments

Li, Z., Krippendorff, B., & Shah, D. K. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2219-y · Cited by 67 · see citing works

89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo

Jauw, Y. W. S., O’Donoghue, J. A., Zijlstra, J. M., Hoekstra, O. S., van Oordt, C. W. M. D. H., Morschhauser, F., Carrasquillo, J. A., Zweegman, S., Pandit-Taskar, N. D., Lammertsma, A. A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224568 · Cited by 66 · see citing works

Simulation of Monoclonal Antibody Pharmacokinetics in HumansUsing a Minimal Physiologically Based Model

Li, L., Gardner, I. B., Dostálek, M., & Jamei, M. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9640-5 · Cited by 63 · see citing works

DARPins: Promising Scaffolds for Theranostics

Shilova, O. N., & Deyev, S. M. (2019) · Acta Naturae · doi:10.32607/20758251-2019-11-4-42-53 · Cited by 62 · see citing works

Toward Sensitive and Accurate Analysis of Antibody Biotherapeutics by Liquid Chromatography Coupled with Mass Spectrometry

An, B., Zhang, M., & Qu, J. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058917 · Cited by 61 · see citing works

CGRP Monoclonal Antibodies for Migraine: Rationale and Progress

Yuan, H., Lauritsen, C. G., Kaiser, E. A., & Silberstein, S. D. (2017) · BioDrugs · doi:10.1007/s40259-017-0250-5 · Cited by 60 · see citing works

Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein

Moyers, J. S., Hansen, R. J., Day, J. W., Dickinson, C. D., Zhang, C., Ruan, X., Ding, L., Brown, R. M., Baker, H. E., & Beals, J. M. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001105 · Cited by 61 · see citing works

Application of Transmural Flow Across In Vitro Microvasculature Enables Direct Sampling of Interstitial Therapeutic Molecule Distribution

Offeddu, G. S., Possenti, L., Loessberg-Zahl, J., Zunino, P., Roberts, J., Han, X., Hickman, D., Knutson, C. G., & Kamm, R. D. (2019) · Small · doi:10.1002/smll.201902393 · Cited by 54 · see citing works

Interstitial IgG antibody pharmacokinetics assessed by combined in vivo‐ and physiologically‐based pharmacokinetic modelling approaches

Eigenmann, M. J., Karlsen, T. V., Krippendorff, B., Tenstad, O., Fronton, L., Otteneder, M. B., & Wiig, H. (2017) · The Journal of Physiology · doi:10.1113/jp274819 · Cited by 56 · see citing works

Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics

Shah, D. K. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9447-8 · Cited by 55 · see citing works

Impact of blood-brain barrier permeabilization induced by ultrasound associated to microbubbles on the brain delivery and kinetics of cetuximab: An immunoPET study using 89Zr-cetuximab

Tran, V. L., Novell, A., Tournier, N., Gerstenmayer, M., Schweitzer-Chaput, A., Mateos, C., Jégo, B., Bouleau, A., Nozach, H., Winkeler, A., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.047 · Cited by 54 · see citing works

In Translation: FcRn across the Therapeutic Spectrum

Qi, T., & Cao, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063048 · Cited by 53 · see citing works

An anti-CTLA-4 heavy chain–only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile

Gan, X., Shan, Q., Li, H., Janssens, R., Shen, Y., He, Y., Chen, F., van Haperen, R., Drabek, D., Li, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200879119 · Cited by 51 · see citing works

Human Antibodies for Viral Infections

Crowe, J. E. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041309 · Cited by 52 · see citing works

Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults

Phuah, J. Y., Maas, B. M., Tang, A., Zhang, Y., Caro, L., Railkar, R. A., Swanson, M. D., Cao, Y., Li, H., Roadcap, B. A., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115851 · Cited by 50 · see citing works

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Fourie, A. M., Cheng, X., Chang, L., Greving, C. N. A., Li, X., Knight, B., Polidori, D., Patrick, A. N., Bains, T., Steele, R. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67371-5 · Cited by 50 · see citing works

Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics

Li, Z., & Shah, D. K. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09639-2 · Cited by 50 · see citing works

Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy

Ye, Q., Wang, Y., Shen, S., Xu, C., & Wang, J. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002139 · Cited by 49 · see citing works

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

Шульгин, Б. В., Kosinsky, Y., Omelchenko, A. V., Chu, L., Mugundu, G. M., Aksenov, S., Pimentel, R., DeYulia, G., Kim, G., Peskov, K. V., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1748982 · Cited by 49 · see citing works

Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations

Chang, H., Kim, S. J., & Shah, D. K. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.05.025 · Cited by 48 · see citing works

Review on modeling anti-antibody responses to monoclonal antibodies

Gómez‐Mantilla, J. D., Trocóniz, I. F., Parra-Guillen, Z. P., & Garrido, M. J. (2014) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9367-z · Cited by 47 · see citing works

Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice

Gaikwad, S., Puangmalai, N., Sonawane, M., Montalbano, M., Price, R., Iyer, M. S., Ray, A., Moreno, S., & Kayed, R. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj5958 · Cited by 46 · see citing works

Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice

Khot, A., Matsueda, S., Thomas, V. A., Koya, R. C., & Shah, D. K. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.252858 · Cited by 46 · see citing works

PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study

Suhr, O. B., Grogan, M. A., SILVA, A. C. F. D., Karam, C., García‐Pavía, P., Drachman, B., Zago, W. M., Tripuraneni, R., & Kinney, G. G. (2024) · Amyloid · doi:10.1080/13506129.2024.2420809 · Cited by 44 · see citing works

Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models

Fronton, L., Pilari, S., & Huisinga, W. (2014) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9349-1 · Cited by 44 · see citing works

Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection

Sadekar, S., Figueroa, I., & Tabrizi, M. A. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9766-0 · Cited by 43 · see citing works

Assessments of antibody biodistribution

Glassman, P. M., Abuqayyas, L., & Balthasar, J. P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.365 · Cited by 42 · see citing works

Granulocyte–macrophage colony‐stimulating factor ( GM ‐ CSF ) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐ GM ‐ CSF monoclonal antibody

Papp, K. A., Gooderham, M., Jenkins, R., Vender, R. B., Szepietowski, J. C., Wagner, T., Hunt, B., Souberbielle, B. E., & on behalf of the NEPTUNE investigators (2018) · British Journal of Dermatology · doi:10.1111/bjd.17195 · Cited by 42 · see citing works

Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis

Chang, H.-Y., Wu, S., Li, Y., Zhang, W., Burrell, M. R., Webster, C. I., & Shah, D. K. (2021) · mAbs · doi:10.1080/19420862.2021.1874121 · Cited by 42 · see citing works

Beware of Mycoplasma Anti-immunoglobulin Strategies

Arfi, Y., Lartigue, C., Sirand‐Pugnet, P., & Blanchard, A. (2021) · mBio · doi:10.1128/mbio.01974-21 · Cited by 41 · see citing works

Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis

Jadhav, S. B., Khaowroongrueng, V., Fueth, M., Otteneder, M. B., Richter, W., & Derendorf, H. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.03.033 · Cited by 41 · see citing works

The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2

Ryu, D.-K., Kang, B., Noh, H., Woo, S., Lee, M., Nuijten, P. M., Kim, J., Seo, J.-M., Kim, C.-M., Kim, M., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.023 · Cited by 40 · see citing works

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

Wechalekar, A., Antoni, G., Al-Azzam, W. A., Bergström, M., Biswas, S., Chen, C.-G., Cheriyan, J., Cleveland, M., Cookson, L., Galette, P., et al. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02407-6 · Cited by 29 · see citing works

Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling

Sachen, K. L., Hammaker, D. R., Sarabia, I., Stoveken, B., Hartman, J., Leppard, K. L., Manieri, N. A., Bao, P., Greving, C. N. A., Lacy, E. R., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1532852 · Cited by 38 · see citing works

The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation

Conner, K. P., Devanaboyina, S. C., Thomas, V. A., & Rock, D. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107574 · Cited by 38 · see citing works

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection

Chigutsa, E., O’Brien, L. M., Ferguson‐Sells, L. R., Long, A. J., & Chien, J. Y. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2420 · Cited by 38 · see citing works

Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO‐029 Antibody for Muscular Dystrophy

Singh, P., Rong, H., Gordi, T., Bosley, J., & Bhattacharya, I. (2016) · Clinical and Translational Science · doi:10.1111/cts.12420 · Cited by 37 · see citing works

Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain

Kuchimanchi, M., Monine, M. I., Muralidharan, K. K., Woodward, C. N., & Penner, N. A. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12538 · Cited by 37 · see citing works

Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions

Tang, Y., & Cao, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030422 · Cited by 38 · see citing works

Nano‐ and Micro‐Platforms in Therapeutic Proteins Delivery for Cancer Therapy: Materials and Strategies

Han, H., & Santos, H. A. (2024) · Advanced Materials · doi:10.1002/adma.202409522 · Cited by 36 · see citing works

Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1

Khot, A., Tibbitts, J., Rock, D. A., & Shah, D. K. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0131-3 · Cited by 36 · see citing works

Immune responses to dengue virus in the skin

Rathore, A. P. S., & John, A. L. S. (2018) · Open Biology · doi:10.1098/rsob.180087 · Cited by 36 · see citing works

Transport study of interleukin-1 inhibitors using a human in vitro model of the blood-brain barrier

Sjöström, E. O., Culot, M., Leickt, L., Åstrand, M., Nordling, E., Gosselet, F., & Kaiser, C. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100307 · Cited by 36 · see citing works

Advances and challenges in immunoPET methodology

Mohr, P., van Sluis, J., Hooge, M. L.-D., Lammertsma, A., Brouwers, A., & Tsoumpas, C. (2024) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2024.1360710 · Cited by 35 · see citing works

GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice

Liu, C. M., Killion, E. A., Hammoud, R., Lu, S.-C., Komorowski, R., Liu, T., Kanke, M., Thomas, V. A., Cook, K. D., Sivits, G. N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01295-w · Cited by 37 · see citing works

Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer’s Disease and Multiple Sclerosis

Etxeberria, A., Shen, Y.-A. A., Vito, S., Silverman, S. M., Imperio, J., Lalehzadeh, G., Soung, A. L., Du, C., Xie, L., Choy, M. K., et al. (2024) · The Journal of Neuroscience · doi:10.1523/jneurosci.2347-23.2024 · Cited by 34 · see citing works

A Revisit to the Pretargeting Concept—A Target Conversion

Liu, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01476 · Cited by 33 · see citing works

Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology

Li, T. R., Chatterjee, M. S., Lala, M., Abraham, A. K., Freshwater, T., Jain, L., Sinha, V. P., de Alwis, D. P., & Mayawala, K. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2170 · Cited by 33 · see citing works

Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies

Kratochwil, N. A., Dueker, S. R., Muri, D., Senn, C., Yoon, H., Yu, B. Y., Lee, G., Dong, F., & Otteneder, M. B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205435 · Cited by 32 · see citing works

Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model

Geerts, H., Bergeler, S., Walker, M., van der Graaf, P. H., & Courade, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-41382-0 · Cited by 31 · see citing works

The Use of Microdosing in the Development of Small Organic and Protein Therapeutics

Bergström, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188037 · Cited by 31 · see citing works

Reciprocal immune enhancement of dengue and Zika virus infection in human skin

Castanha, P. M. S., Erdös, G., Watkins, S. C., Falo, L. D., Marques, E. T. A., & Barratt‐Boyes, S. M. (2020) · JCI Insight · doi:10.1172/jci.insight.133653 · Cited by 31 · see citing works

Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies

Rafidi, H., Rajan, S., Urban, K., Shatz-Binder, W., Hui, K. S. F., Ferl, G. Z., Kamath, A. V., & Boswell, C. A. (2022) · mAbs · doi:10.1080/19420862.2022.2085535 · Cited by 28 · see citing works

Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice

Chang, H., Li, Z., & Shah, D. K. (2022) · Pharmaceutical Research · doi:10.1007/s11095-021-03162-1 · Cited by 28 · see citing works

Optimization of Human Dose Prediction by Using Quantitative and Translational Pharmacology in Drug Discovery

Bueters, T., Gibson, C. R., & Visser, S. A. G. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.143 · Cited by 27 · see citing works

A Therapeutic Antiviral Antibody Inhibits the Anterograde Directed Neuron-to-Cell Spread of Herpes Simplex Virus and Protects against Ocular Disease

Bauer, D., Alt, M., Dirks, M., Buch, A., Heilingloh, C. S., Dittmer, U., Giebel, B., Görgens, A., Palapys, V., Kasper, M., et al. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02115 · Cited by 26 · see citing works

Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies

Chudasama, V. L., Zutshi, A., Singh, P., Abraham, A. K., Mager, D. E., & Harrold, J. M. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9401-1 · Cited by 26 · see citing works

New challenges and opportunities in nonclinical safety testing of biologics

Baumann, A., Flagella, K. M., Forster, R. P., de Haan, L., Kronenberg, S., Locher, M., Richter, W., Theil, F., & Todd, M. D. (2014) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2014.04.005 · Cited by 26 · see citing works

Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities

Rock, B. M., & Foti, R. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.088708 · Cited by 26 · see citing works

Investigating surrogate cerebrospinal fluid matrix compositions for use in quantitative LC-MS analysis of therapeutic antibodies in the cerebrospinal fluid

Fogh, J. R., Jacobsen, A., Nguyen, T. T. T. N., Rand, K. D., & Olsen, L. R. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02403-3 · Cited by 25 · see citing works

Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper

Ménochet, K., Yu, H., Wang, B., Tibbitts, J., Hsu, C., Kamath, A. V., Richter, W. F., & Baumann, A. (2022) · mAbs · doi:10.1080/19420862.2022.2145997 · Cited by 25 · see citing works

Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study

Wu, X., Li, N., Wang, G., Liu, W. Y., Yu, J., Cao, G., Wang, J., Chen, Y., Ma, J., Wu, J., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00350-21 · Cited by 23 · see citing works

Sabatolimab ( MBG453 ) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors

Xu, S., Zhang, N., Rinne, M. L., Sun, H., & Stein, A. M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12962 · Cited by 23 · see citing works

Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination

Fromm, G. J., de Silva, S., Giffin, L., Xu, X., Rose, J., & Schreiber, T. H. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0228 · Cited by 23 · see citing works

Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects

Criscuolo, E., Castelli, M., Diotti, R. A., Amato, V., Burioni, R., Clementi, M., Ambrosi, A., Mancini, N., & Clementi, N. (2019) · Journal of Virology · doi:10.1128/jvi.00070-19 · Cited by 23 · see citing works

A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial

Chigutsa, E., Jordie, E. B., Riggs, M. M., Nirula, A., Elmokadem, A., Knab, T., & Chien, J. Y. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2459 · Cited by 22 · see citing works

Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling

Tiwari, A., Abraham, A. K., Harrold, J. M., Zutshi, A., & Singh, P. (2016) · The AAPS Journal · doi:10.1208/s12248-016-0004-1 · Cited by 22 · see citing works

Pharmacokinetic and biodistribution analysis of monoclonal antibodies: a comprehensive study of antibody biodistribution and partitioning coefficients in mice

Rabow, Z., Samiee, I., Desai, P., Liu, X., Thomas, M., Khawli, L. A., & Carr, B. (2025) · mAbs · doi:10.1080/19420862.2025.2587580 · Cited by 1 · see citing works

Prediction of tissue concentrations of monoclonal antibodies in mice from plasma concentrations

Mahmood, I., & Tegenge, M. A. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.06.004 · Cited by 2 · see citing works

Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations

Chang, H., Kim, S. J., & Shah, D. K. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.05.025 · Cited by 48 · see citing works

Assessments of antibody biodistribution

Glassman, P. M., Abuqayyas, L., & Balthasar, J. P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.365 · Cited by 42 · see citing works

Comparison of monoclonal antibody disposition predictions between different PBPK platforms

De Sutter, P.-J., Gasthuys, E., & Vermeulen, A. (2023) · Ghent University Academic Bibliography (Ghent University)